{"id":64238,"date":"2026-05-12T18:06:35","date_gmt":"2026-05-12T18:06:35","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/64238\/"},"modified":"2026-05-12T18:06:35","modified_gmt":"2026-05-12T18:06:35","slug":"roche-gets-second-european-approval-for-alzheimers-test-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/64238\/","title":{"rendered":"Roche gets second European approval for Alzheimer&#8217;s test"},"content":{"rendered":"<p><a data-ylk=\"elm:icon;slk:Reuters;\" href=\"https:\/\/www.reuters.com\/\" target=\"_blank\" rel=\"nofollow noopener\"><img alt=\"Reuters\" loading=\"lazy\" width=\"171\" height=\"40\" decoding=\"async\" data-nimg=\"1\" class=\"pr-2.5 max-w-[150px] max-h-[40px] min-[601px]:max-w-[115px]\" style=\"color:transparent;max-width:auto;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/https:\/\/s.yimg.com\/os\/creatr-uploaded-images\/2020-11\/62e21440-2fbd-11eb-95ff-5673fa3d2f9f.jpeg\"\/><\/a>Tue, May 12, 2026 at 5:08 AM UTC<img alt=\"\" loading=\"lazy\" width=\"976\" height=\"566\" decoding=\"async\" data-nimg=\"1\" class=\"standard-img w-full w-full h-auto\" style=\"color:transparent\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/https:\/\/media.zenfs.com\/en\/reuters.com\/f7d971d187aefe2d95ef4fb63132ba99.jpeg\"\/><\/p>\n<p>FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS\/Arnd Wiegmann\/File Photo<\/p>\n<p>ZURICH, May 12 (Reuters) &#8211; Swiss drugmaker Roche has received the CE mark &#8211; a \u200cEuropean regulatory clearance allowing sale in \u200cthe region &#8211; for its second Elecsys blood test for \u200bAlzheimer&#8217;s disease, it said on Tuesday.<\/p>\n<p>The test was developed with U.S. company Eli Lilly.<\/p>\n<p>\u2022 Compared with its already approved pTau181 test, \u200cwhich mainly helps \u2060rule out Alzheimer&#8217;s-related amyloid pathology, the newer pTau217 test can both \u2060help confirm and exclude the disease. It is validated for use in both primary \u200band specialist \u200bcare.<\/p>\n<p>\u2022 The test \u200bhas already received breakthrough \u200cdevice designation from the U.S. FDA.<\/p>\n<p>\u2022 Blood tests could speed diagnosis and widen access to treatments such as Biogen and Eisai&#8217;s Leqembi and Eli Lilly&#8217;s Kisunla, as current \u200cdiagnostic methods are often \u200bcostly or uncomfortable.<\/p>\n<p>\u2022 Roche \u200bsaid an estimated \u200b75% of people living with \u200cdementia remain undiagnosed.<\/p>\n<p>\u2022 The test \u200bis expected \u200bto become available in CE-marked markets from July, Olivier Gillieron, life cycle leader \u200bin cardiometabolic \u200cand neurology at Roche told media \u200bin a call.<\/p>\n<p>(Reporting by Marleen Kaesebier. \u200bEditing by Mark Potter)<\/p>\n","protected":false},"excerpt":{"rendered":"Tue, May 12, 2026 at 5:08 AM UTC FILE PHOTO: The logo of Swiss drugmaker Roche is seen&hellip;\n","protected":false},"author":2,"featured_media":64239,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[13066,14442,216,134,15704],"class_list":{"0":"post-64238","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-alzheimer39s-disease","9":"tag-blood-test","10":"tag-eli-lilly","11":"tag-roche","12":"tag-test"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116562938135580090","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=64238"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64238\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/64239"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=64238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=64238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=64238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}